|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 868.10 INR | -1.77% |
|
-2.99% | -5.06% |
| Capitalization | 874B 9.63B 8.3B 7.73B 7.19B 13.39B 14.41B 88.87B 35.04B 417B 36.1B 35.36B 1,521B | P/E ratio 2026 * |
19x | P/E ratio 2027 * | 21.1x |
|---|---|---|---|---|---|
| Enterprise value | 844B 9.31B 8.02B 7.47B 6.95B 12.94B 13.93B 85.9B 33.87B 403B 34.9B 34.18B 1,471B | EV / Sales 2026 * |
3.28x | EV / Sales 2027 * | 2.96x |
| Free-Float |
24.85% | Yield 2026 * |
0.8% | Yield 2027 * | 0.77% |
Last Transcript: Zydus Lifesciences Limited
| 1 day | -1.77% | ||
| 1 week | -2.99% | ||
| Current month | -5.06% | ||
| 1 month | -5.45% | ||
| 3 months | -12.10% | ||
| 6 months | -11.67% | ||
| Current year | -5.06% |
| 1 week | 865.4 |  | 902.05 |
| 1 month | 865.4 | | 941 |
| Current year | 865.4 | | 941 |
| 1 year | 795 | | 1,059.05 |
| 3 years | 421.3 | | 1,324.3 |
| 5 years | 319 | | 1,324.3 |
| 10 years | 202 | | 1,324.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 2009-11-26 | |
| Director of Finance/CFO | 65 | - | |
| Director of Finance/CFO | 56 | 2025-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 46 | 2007-03-31 | |
| Director/Board Member | 71 | 1997-07-31 | |
| Chairman | 73 | 2011-10-04 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +4.72% | 0.01% | 51 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.77% | -2.99% | -12.72% | +101.21% | 9.63B | |
| -1.87% | -3.53% | -6.59% | +61.61% | 44.13B | |
| +1.97% | +2.51% | +52.27% | - | 33.32B | |
| -2.07% | -0.83% | +13.23% | +121.06% | 30.13B | |
| -2.58% | -4.65% | -3.11% | +30.72% | 12.44B | |
| -0.68% | -3.97% | +73.06% | +46.33% | 8.4B | |
| +0.91% | +3.27% | +48.82% | +129.73% | 7.81B | |
| -.--% | +0.14% | - | - | 6.79B | |
| -0.77% | -0.53% | +39.62% | -20.21% | 6.72B | |
| -0.53% | -0.32% | +36.28% | +380.30% | 6.22B | |
| Average | -0.74% | -1.05% | +26.76% | +106.34% | 16.56B | |
| Weighted average by Cap. | -0.82% | -1.16% | +19.99% | +90.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 257B 2.83B 2.44B 2.27B 2.12B 3.94B 4.24B 26.16B 10.31B 123B 10.63B 10.41B 448B | 273B 3.01B 2.59B 2.41B 2.25B 4.18B 4.5B 27.77B 10.95B 130B 11.28B 11.05B 475B |
| Net income | 46.54B 513M 442M 412M 383M 714M 768M 4.74B 1.87B 22.2B 1.92B 1.88B 81.06B | 41.72B 460M 396M 369M 344M 640M 688M 4.24B 1.67B 19.9B 1.72B 1.69B 72.66B |
| Net Debt | -29.22B -322M -278M -258M -241M -448M -482M -2.97B -1.17B -13.94B -1.21B -1.18B -50.89B | -65.92B -726M -626M -583M -543M -1.01B -1.09B -6.71B -2.64B -31.44B -2.72B -2.67B -115B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 868.10 ₹ | -1.77% | 1,052,948 |
| 26-01-14 | 883.75 ₹ | -1.88% | 728,209 |
| 26-01-13 | 900.70 ₹ | +0.63% | 493,965 |
| 26-01-12 | 895.05 ₹ | +0.02% | 424,551 |
| 26-01-09 | 894.90 ₹ | -1.39% | 797,148 |
Delayed Quote NSE India S.E., January 16, 2026 at 05:17 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZYDUSLIFE Stock
Select your edition
All financial news and data tailored to specific country editions
